July 23rd 2018
March 14th 2018
January 1st 2018
September 1st 2017
This webinar is intended to provide members of the press in Europe with an overview of the ATMP landscape in Europe, including major financings, the clinical pipeline, and the potential for these therapies to significantly improve the standard of care for many patients suffering from devastating diseases and disorders. The webinar also provides a brief introduction to ARM and ARM’s role in improving the landscape for ATMPs in Europe and globally.
Gain a deeper understanding of the implications of the Regenerative Medicine Advanced Therapies (RMAT) designation and the significance of its support and advancement by the FDA in this webinar recording. Held in partnership with the Alliance for Regenerative Medicine (ARM), ARM, Informa Pharma Intelligence, and representative from Abeona, Athersys, and Enzyvant discuss the RMAT designation and its implications on the sector.
Michael Werner, Co-Founder and Senior Policy Counsel for ARM, and Robert Falb, Director of U.S. Policy and Advocacy, participated in BIO’s webinar on NTAP and advanced therapies on May 9. ARM believes that it is critical that the NTAP program be modernized to facilitate patient access to new and life-saving treatments.
CAR-T cell therapy is now approved in the U.S. The first product, Novartis’ Kymriah, is approved to treat pediatric and young adult patients with B-cell acute lymphoblastic lymphoma, and products for other oncological indications are hot on its heels. Join Informa Pharma Intelligence and ARM for an interactive webinar to explore what this historic approval means for the patient community, as well as how this sector will approach the scientific, clinical, policy and business issues surrounding CAR-T approvals.
HHS: OIG Proposed Rule on the Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Comments
April 2019